Microbot Medical Highlights Strategic Growth Initiatives and Expansion Plans
Microbot Medical is continuing to advance its commercial expansion strategy as it works to increase adoption of its LIBERTY® Endovascular Robotic System across healthcare systems in the United States and selected international markets.
The medical technology company recently highlighted the progress of its commercial and growth strategy during an analyst meeting held in New York City on September 24, 2026. During the meeting, Microbot Medical discussed several areas of its business development strategy, including expansion of its U.S. sales organization, engagement with hospital Value Analysis Committees, manufacturing improvements, international market opportunities and preparations for future regulatory milestones.
The company also highlighted selected findings from a user survey that is available through its website. According to the company, the survey results indicated a high level of satisfaction with the LIBERTY System among users.
The latest update provides insight into how Microbot Medical is working to build its commercial infrastructure while preparing for broader adoption of its robotic technology in peripheral endovascular procedures.
Expanding the U.S. Commercial Footprint
One of the major areas highlighted by Microbot Medical was the continued expansion of its U.S. commercial footprint.
The company said it remains on track to establish 12 sales territories by the end of 2026. The expansion is intended to support commercial growth and allow Microbot Medical to engage with a broader range of hospitals and healthcare systems.
The company is also supporting its first customer in California while continuing its expansion in North Carolina. These developments represent steps in the company’s strategy to broaden the geographic reach of the LIBERTY System and increase engagement with hospitals that perform peripheral endovascular procedures.
Expanding a commercial organization is an important part of the commercialization process for medical technology companies. In addition to providing direct sales coverage, regional teams can help companies establish relationships with clinicians, hospital administrators and purchasing stakeholders.
For Microbot Medical, the planned expansion to 12 sales territories is designed to create additional coverage as the company seeks to increase awareness and adoption of its robotic platform.
Earlier Engagement With Hospital Value Analysis Committees
Microbot Medical also discussed changes to its commercial strategy during the analyst meeting.
The company said it has evolved its approach to engage hospital Value Analysis Committee, or VAC, processes earlier in the sales cycle. Based on the company’s current experience, the VAC process typically takes approximately four to six months.
Value Analysis Committees play an important role in many healthcare organizations when evaluating medical technologies and other products for potential adoption. These committees can consider factors such as clinical value, operational requirements, financial considerations and the potential impact of a technology on a hospital system.
By engaging with VAC processes earlier, Microbot Medical aims to establish a pathway toward broader access to hospital systems.
The company said it is currently engaged with Value Analysis Committees at multiple health systems. This strategy is particularly relevant for healthcare organizations operating multiple hospitals, because successful evaluation and approval at the system level can potentially support broader deployment across affiliated facilities.
Microbot Medical believes that earlier engagement with these committees can help accelerate adoption of the LIBERTY System within larger healthcare systems.
Strengthening the Sales Organization
To support its expanding commercial footprint, Microbot Medical has added personnel to its sales organization.
The company has hired three additional Area Sales Managers and an additional Regional Sales Director. These new appointments are intended to support new sales territories and help the company expand its commercial presence toward western regions of the United States.
The addition of sales leadership and regional managers reflects the company’s efforts to build the organizational infrastructure required for commercialization.
For a medical device company transitioning from product development and regulatory clearance toward broader market adoption, commercial infrastructure can be an important component of long-term growth. Sales representatives and regional leadership teams can work directly with hospitals and clinicians to introduce the technology, support evaluation processes and facilitate adoption.
Microbot Medical’s latest hiring activity is therefore aligned with its broader objective of expanding the geographic reach of LIBERTY.
Focus on Manufacturing Efficiency
Alongside commercial expansion, Microbot Medical is also working to improve its manufacturing operations.
The company said it continues to advance operating efficiencies, including the addition of a second manufacturing line and the implementation of more efficient manufacturing processes.
Manufacturing capacity and efficiency become increasingly important as medical technology companies move toward higher commercial volumes. As demand grows, manufacturers need to ensure that production processes can support increased output while maintaining the required quality and consistency.
Microbot Medical expects its manufacturing initiatives to contribute to positive gross margins in 2027.
The planned second manufacturing line is part of the company’s broader effort to improve its production capabilities. More efficient manufacturing processes are also expected to support the company’s financial objectives as commercialization progresses.
Improving manufacturing efficiency can provide benefits beyond capacity alone. Streamlined production processes may help companies better manage resources, improve operational consistency and prepare for potential increases in demand.
International Expansion Opportunities
Microbot Medical is also evaluating opportunities to expand into international markets.
According to the company, potential expansion into selected international markets, including countries in Asia and the Middle East, is at an advanced stage.
The company expects to leverage its existing U.S. Food and Drug Administration clearance as it explores opportunities in these markets. Regulatory requirements differ between jurisdictions, and market entry depends on applicable local regulations and approvals.
The potential international expansion represents another component of Microbot Medical’s longer-term growth strategy.
While the company’s current commercial expansion is focused significantly on the United States, international markets could provide additional opportunities for the LIBERTY System as the company progresses through relevant regulatory and commercial processes.
Asia and the Middle East have been identified by the company as areas where it is advancing potential market opportunities.
Continued Work Toward CE Mark Approval
Microbot Medical is also continuing discussions with regulatory authorities in support of future CE mark approval.
The company expects CE mark approval in late fourth quarter of 2026 or early first quarter of 2027.
A CE mark is relevant to market access in applicable European regulatory environments, and the anticipated milestone is therefore an important part of the company’s international strategy.
Microbot Medical’s continued engagement with regulatory bodies reflects its efforts to prepare the LIBERTY System for potential expansion into additional markets.
The expected regulatory timeline remains an important milestone for the company as it develops its international commercialization strategy.
LIBERTY System and Robotic Endovascular Procedures
At the center of Microbot Medical’s commercial strategy is the LIBERTY System.
The company describes LIBERTY as the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures.
The system is designed for vascular navigation and is intended to provide physicians with robotic control during peripheral endovascular procedures.
According to Microbot Medical, the system is designed to support precise vascular navigation while aiming to reduce radiation exposure and physical strain.
These features are central to the company’s value proposition as it seeks to introduce robotic technology into peripheral vascular procedures.
Robotic technologies are being developed across different areas of healthcare with the goal of supporting clinicians and improving procedural workflows. In the endovascular field, systems such as LIBERTY are designed to provide an alternative approach to conventional manual catheter and guidewire manipulation.
Microbot Medical’s strategy is focused on increasing awareness and adoption of its technology among healthcare providers and hospital systems.
User Survey Highlights System Satisfaction
During its analyst meeting, Microbot Medical also highlighted selected findings from a user survey.
The company said the survey showed high satisfaction with the LIBERTY System among users. The complete survey information is available on the company’s website.
User feedback can provide medical technology companies with information about how clinicians and other healthcare professionals experience a product in practice.
For Microbot Medical, positive user satisfaction results are relevant to its commercialization efforts because the company is seeking to expand the use of LIBERTY across additional hospitals and healthcare systems.
As the company continues to develop its commercial organization, user experience and feedback can also contribute to product education and discussions with prospective customers.
The survey results highlighted during the analyst meeting therefore form another part of Microbot Medical’s broader commercial narrative.
Building Toward Wider Hospital Adoption
Microbot Medical’s strategy involves more than simply increasing the number of sales territories. The company is also working to understand and navigate the purchasing processes used by large healthcare organizations.
The earlier engagement with Value Analysis Committees is particularly relevant in this context.
Large hospital systems often involve multiple stakeholders when evaluating new technologies. Clinical teams, administrators, procurement departments and value analysis groups may all have roles in determining whether a medical device should be adopted.
By becoming involved earlier in the VAC process, Microbot Medical aims to improve the pathway through which health systems evaluate the LIBERTY System.
The company is already engaged with VACs at multiple health systems, according to its latest update.
This approach also aligns with the company’s expansion into regions where it can establish relationships with larger healthcare organizations and potentially support adoption across multiple facilities.
Combining Commercial and Operational Growth
The initiatives highlighted during the analyst meeting demonstrate that Microbot Medical is pursuing growth across several areas simultaneously.
The company is expanding its U.S. sales organization, strengthening its regional leadership, engaging hospital decision-making committees earlier, improving manufacturing operations and exploring international markets.
Each of these initiatives addresses a different element of commercialization.
The sales organization supports customer acquisition and market development. Value Analysis Committee engagement addresses the hospital purchasing process. Manufacturing improvements focus on operational efficiency and production capacity. International regulatory activity supports future geographic expansion.
Together, these initiatives form the company’s broader commercial and growth strategy.
Outlook for 2027
The company’s plans also extend into 2027.
Microbot Medical expects its manufacturing initiatives to contribute to positive gross margins during 2027. At the same time, the company is preparing for potential international expansion and anticipates CE mark approval in late Q4 2026 or early Q1 2027.
If achieved according to the company’s current timeline, these milestones would provide additional elements to its commercialization strategy.
The company is also continuing to expand its U.S. sales footprint, with 12 territories targeted by the end of 2026. This expansion provides the foundation for further commercial activity as the company enters 2027.
The combination of a larger sales organization, increased manufacturing capacity and potential international market access represents the next stage of Microbot Medical’s growth strategy.
Medical Technology Commercialization Remains a Key Focus
For Microbot Medical, the current phase represents a transition from establishing regulatory clearance and product availability toward expanding commercial adoption.
The LIBERTY System’s FDA clearance provides the regulatory foundation for its U.S. commercialization strategy. The company is now focused on building sales coverage, engaging healthcare systems, supporting customers and improving manufacturing efficiency.
The company’s approach also demonstrates the importance of hospital purchasing processes in the medical technology market. Engaging Value Analysis Committees can be an important step when companies seek adoption within large healthcare organizations.
Microbot Medical’s decision to engage these committees earlier reflects its effort to align its commercial process with the way health systems evaluate new technologies.
At the same time, the company’s planned expansion into additional international markets demonstrates an effort to broaden the potential market for LIBERTY beyond the United States.
Microbot Medical’s September 24, 2026 analyst meeting provided an overview of the company’s ongoing commercial and growth strategy.
The company is continuing to expand its U.S. presence and expects to reach 12 sales territories by the end of the year. It is supporting its first customer in California and expanding its presence in North Carolina while adding three Area Sales Managers and a Regional Sales Director to strengthen its sales organization.
The company is also changing its commercial approach by engaging hospital Value Analysis Committees earlier in the purchasing process. Microbot Medical said it is currently involved with VAC processes at multiple health systems and believes earlier engagement can support broader adoption of LIBERTY.
Operational efficiency is another major focus. The planned addition of a second manufacturing line and more efficient production processes are expected to improve manufacturing capabilities, with the company anticipating positive gross margins in 2027.
Internationally, Microbot Medical is advancing potential opportunities in Asia and the Middle East while continuing regulatory engagement related to future CE mark approval. The company currently expects that approval in late Q4 2026 or early Q1 2027.
At the center of these initiatives is the LIBERTY System, which Microbot Medical describes as the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures. The system is designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain.
The company also highlighted positive user survey results indicating high satisfaction with the system. As Microbot Medical continues to expand its commercial organization and pursue additional hospital and international opportunities, customer feedback, manufacturing improvements and regulatory progress will remain important components of its growth strategy.
Source link: https://ir.microbotmedical.com/
